W W Grainger Inc vs uniQure N.V. Ordinary Shares — how do they compare? W W Grainger Inc trades at $1,330.68 (market cap $62.41B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: W W Grainger Inc is far larger — about 42.2× uniQure N.V. Ordinary Shares's market cap, and W W Grainger Inc pays a 0.75% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 26 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GWW | QURE | |
|---|---|---|
Market Cap | $62.41B | $1.48B |
Volume | 284,715 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $1.40K | $70.59 |
52-Week Low | $918.18 | $9.03 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $64.62B | $728.62M |
Dividend Yield | 0.75% | — |
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,325.10, up 1.41% today, with a bullish technical signal and strong fundamentals including a 47.92% ROE and 9.92% net income margin. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a solid dividend as a Dividend King. Institutional buying and positive analyst coverage support the stock's momentum.
Outlook remains positive with a consensus price target of $1,310, though high valuation multiples and competitive pressures pose risks. Earnings growth and market share gains in industrial distribution are key drivers for continued upside.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →